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Lack of Association Between Promoter Polymorphism of the
Tumor Necrosis Factor-a Gene and Psoriatic Arthritis in
Japanese Patients
To the Editor:
The analysis of population-speci®c human leukocyte antigen
(HLA) has provided evidence that susceptibility to psoriasis is
linked to HLA with racial differences (Henseler, 1997). Tumor
necrosis factor-a (TNF-a) gene is also mapped within the HLA
region and its product has been reported as one of the most
important cytokines in the pathogenesis of psoriasis (Uyemura
et al, 1993). Recently, HoÈhler et al (1997) reported in this
journal a signi®cant increase of subjects carrying A at position -
238 of TNF-a gene promoter region in the psoriatic arthritis
(PsA) group, as well as in that of early-onset psoriasis vulgaris
(PsV). These ®ndings, however, are still controversial (Jacob
et al, 1999; HoÈhler, 1999). Jacob et al (1999) have also shown in
the journal that promoter polymorphism at -238 of the TNF-a
gene was not associated with early onset PsV when tested by
the transmission disequilibrium test. Very recently, it has been
demonstrated that an increased frequency of the TNF-238.A (A
at -238) allele detected only in male patients but not in female
patients with early-onset PsV (Reich et al, 2000). On the other
hand, there are only a few reports on whether polymorphism of
the TNF-a promoter region and PsA are associated or not,
because only a few cases are investigated. Moreover, three new
polymorphisms at positions -1031 (T to C change), -863 (C to
A), and -857 (C to T) have been identi®ed in the Japanese
population (Higuchi et al, 1998). In this study we evaluated the
association between promoter polymorphism of the TNF-a
gene and PsA in the Japanese population.
Twenty Japanese patients (eight females and 12 males)
suffering from PsA were studied (the median age was 44 y,
ranged from 25 to 70). The control population consisted of 87
locally recruited, unrelated volunteers (21 female and 67 males
with a median age of 52 y ranged from 15 to 81). Peripheral
blood mononuclear cells were separated by the Ficoll method
for isolation of genomic DNA. A 1042 bp DNA fragment of
the 5¢ ¯anking region of the TNF-a gene at position -1107 to
-66 was ampli®ed by PCR with a sense primer 5¢-
GCTTGTGTGTGTGTGTCTGG-3¢ and an anti-sense primer
5¢-GGACACACAAGCATCAAGG-3¢ (Higuchi et al, 1998).
Polymerase chain reaction (PCR) products were run on
ethidium bromide-stained agarose gel, and then excised DNA
bands from the gel were puri®ed using a GENECLEAN II kit
(BIO 101, La Jolla, CA). These puri®ed PCR products were
directly sequenced by the dideoxy nucleotide dye terminator
cycle sequencing method using two different primers, 5¢-
GCTTGTGTGTGTGTGTCTGG-3¢ (Higuchi et al, 1998) for
the polymorphism at -1031, -863, and -857, and 5¢-
TTCCTGCATCCTGTCTGGAA-3¢ (D'Alfonso and Richiardi,
1994) for those at -308 and -238, respectively.
As shown in Table I, all patients with PsA studied have a
genotype G/G at both -238 and -308, whereas 4.6% (four of 87)
and 3.4% (three of 87) of controls have a genotype G/A at -238 and
-308, respectively. Gene frequencies for the TNF-238A allele in
the Japanese controls were similar to those reported by the authors
for West European Caucasians (2.3% vs 3.5%) (HoÈhler et al, 1997)
and the previous report for Japanese patients (2.3% vs 2.0%)
(Higuchi et al, 1998). The frequencies for the TNF-308A (A at
-308) allele in the Japanese controls, however, were less than those
reported by the authors for West European Caucasians (2.9% vs
10%) (HoÈhlet et al, 1997), whereas no difference was seen between
this study and the previous one (2.9% vs 1.7%) (Higuchi et al,
1998). Furthermore, we found no signi®cant increase of subjects
carrying C, A, and T at positions -1031, -863, and -857,
respectively (Table I). In this region the frequency of alleles
-1031C (C at -1031), -863A (A at -863), and -857T (T at -857) is
similar to that previously reported by Higuchi et al (1998) (12.6% vs
16.0% for -1031C; 15.5% vs 14.0%, -863A; 15.5% vs 17.7%,
-857T).
These results are quite different from those reported by
HoÈhler et al (1997). In their report, 32% (20 in 62) of PsA
patients have genotype G/A at -238, whereas 7% of controls
(seven of 99) have the genotype (HoÈhler et al, 1997). We
calculated on gene frequencies for the TNF-238A allele in PsA
patients 16.1% from the data demonstrated. The discrepancy
does not seem to depend on the racial difference, because gene
frequencies for the TNF-238A allele in their controls were not
different from the data by our or other studies (3.5% vs 2.3% or
2.0%) (HoÈhlet et al, 1997; Higuchi et al, 1998). Although a small
number of PsA cases was investigated, this study clearly shows
that promoter polymorphism at -238 of the TNF-a gene is not
associated with PsA in the Japanese population as well as at
other positions, including -1031, -863, -857, and -308.
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In a small study with 20 patients suffering from psoriatic arthritis,
Hammamoto et al have investigated TNF-a promoter polymorph-
isms and failed to con®rm the previously published (HoÈhler et al,
1997; Arias et al, 1997) association of psoriatic arthritis and psoriasis
with a G to A transition polymorphism (TNF238.A) in the TNF-a
promoter region. This polymorphism has attracted particular
interest as it seems to in¯uence the transcription of the TNF-a
gene and decreases the production of TNF-a in particular by T
lymphocytes (Kaluza et al, 2000). We have forwarded the
hypothesis that this polymorphism could be an additional major
histocompatibility complex (MHC) encoded susceptibility factor
for the development of psoriasis favoring persistence of cutaneous
skin infections, e.g. by streptococci. The TNF238A polymorphism
is part of the ancestral haplotype B57.1 (TNF238.A-B57-Cw6) that
has been linked to psoriasis. This is the most common haplotype in
Western European Caucasians with the disease (Jenisch et al, 1999).
In addition, a number of other haplotypes have been associated
with the occurrence of psoriasis, e.g. B13-Cw6, B8-Cw7, and
B37-Cw6 (Jenisch et al, 1999), the latter being the most common
disease associated haplotype in Japan (Imanishi et al, 1992). The
strong haplotype conservation within the MHC makes the
investigation of TNF-a polymorphisms in conjunction with
HLA-B and Cw-alleles mandatory. Unfortunately, Hamamoto
et al do not provide any data concerning HLA-B- and -Cw-allele
haplotypes and frequencies in their psoriatic arthritis group.
Considering the high frequency of the B37-Cw6 haplotype in
Japanese psoriasis patients (Imanishi et al, 1992) it is not surprising
that the authors do not ®nd an association with the TNF238.A
promoter variant, which is almost exclusively found on the B57-
Cw6 haplotype. Nevertheless, the ®ndings of this small study are
interesting as they underline ethnic heterogeneity in the genetics of
psoriasis. These results should be con®rmed in a larger set of
Japanese patients with psoriasis vulgaris and psoriatic arthritis
including HLA-B and Cw alleles in the analysis.
Very recent data by Nair et al (2000) indicate that the MHC
encoded PSORS1 susceptibility locus, which has been con®rmed
in a number of different studies, is located 100 kB telomeric to
HLA-C. This group has identi®ed a 60 kB fragment of the ancestral
haplotype 57.1 that is shared by all identi®able risk haplotypes.
Table I. TNF-a gene promoter polymorphism in 20 Japanese PsA patients and 87 controls
PsA Control
Position Genotype Number (%) Allele (frequency, %) Number (%) Allele (frequency, %)
T/T 16 (80.0) 65 (74.7)
±1,301T (90.0) ±1,301T (87.4)
±1301 T/C 4 (20.0) 22 (25.3)
±1,301C (10.0) ±1,301C (12.6)
C/C 0 (0.0) 0 (0.0)
C/C 15 (75.0) 63 (72.4)
±863C (85.0) ±863C (84.5)
±863 C/A 4 (20.0) 21 (24.1)
±863A (15.0) ±863A (15.5)
A/A 1 (5.0) 3 (3.5)
C/C 14 (70.0) 62 (71.3)
±857C (82.5) ±857C (84.5)
±857 C/T 5 (25.0) 23 (26.4)
±857T (17.5) ±857T (15.5)
T/T 1 (5.0) 2 (2.3)
G/G 20 (100) 83 (95.4)
±308G (100.0) ±308G (97.1)
±308 G/A 0 (0) 3 (3.4)
±308A (0.0) ±308A (2.9)
A/A 0 (0) 1 (5.0)
G/G 20 (100) 83 (95.4)
±238G (100.0) ±238G (97.7)
±238 G/A 0 (0) 4 (4.6)
±238A (0.0) ±238A (2.3)
A/A 0 (0) 0 (0.0)
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